APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Ophthalmic Corticosteroid

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Ophthalmic Corticosteroid Market Outlook and Growth Opportunities 2026

Report ID 174019130429 December 2025192 pages

Choose your research edition.

Industry ResearchOphthalmic Corticosteroid Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Ophthalmic Corticosteroid Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Ophthalmic Corticosteroid Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ophthalmic Corticosteroid Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Ophthalmic Corticosteroid Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Ophthalmic Corticosteroid market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Ophthalmic Corticosteroid is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Ophthalmic Corticosteroid is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Ophthalmic Corticosteroid is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Ophthalmic Corticosteroid market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Ophthalmic Corticosteroid market include Novartis AG, Pfizer, GlaxoSmithKline, Bayer AG, Sun Pharmaceutical, Regeneron Pharmaceuticals, Orchidia, Innovative Pharmaceuticals and General Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Ophthalmic Corticosteroid market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Ophthalmic Corticosteroid and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Ophthalmic Corticosteroid revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Ophthalmic Corticosteroid market.

Ophthalmic Corticosteroid Segment by Company

Novartis AG

Pfizer

GlaxoSmithKline

Bayer AG

Sun Pharmaceutical

Regeneron Pharmaceuticals

Orchidia

Innovative Pharmaceuticals

General Pharmaceuticals

Genentech

Bausch Health

Bausch and Lomb

Allergan

Alimera Sciences

Ajanta Pharma

Ophthalmic Corticosteroid Segment by Type

Dexamethasone

Difluprednate

Fluorometholone

Loteprednol

Others

Ophthalmic Corticosteroid Segment by Application

Hospital Pharmacies

Research Institute

Online Pharmacies

Retail Pharmacies

Others

Ophthalmic Corticosteroid Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Ophthalmic Corticosteroid status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Ophthalmic Corticosteroid key companies, revenue, market share, and recent developments.

3. To split the Ophthalmic Corticosteroid breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Ophthalmic Corticosteroid market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Ophthalmic Corticosteroid significant trends, drivers, influence factors in global and regions.

6. To analyze Ophthalmic Corticosteroid competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ophthalmic Corticosteroid market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ophthalmic Corticosteroid and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ophthalmic Corticosteroid.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Ophthalmic Corticosteroid industry.

Chapter 3: Detailed analysis of Ophthalmic Corticosteroid company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Ophthalmic Corticosteroid in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Ophthalmic Corticosteroid in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Ophthalmic Corticosteroid Industry Trends Table 2. Ophthalmic Corticosteroid Industry Drivers Table 3. Ophthalmic Corticosteroid Industry Opportunities and Challenges Table 4. Ophthalmic Corticosteroid Industry Restraints Table 5. Global Ophthalmic Corticosteroid Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Ophthalmic Corticosteroid Revenue Share by Company (2021-2026) Table 7. Global Ophthalmic Corticosteroid Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Ophthalmic Corticosteroid Key Company Manufacturing Base & Headquarters Table 9. Global Ophthalmic Corticosteroid Company, Product Type & Application Table 10. Global Ophthalmic Corticosteroid Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Ophthalmic Corticosteroid by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Dexamethasone Table 15. Significant Companies of Difluprednate Table 16. Significant Companies of Fluorometholone Table 17. Significant Companies of Loteprednol Table 18. Significant Companies of Others Table 19. Global Ophthalmic Corticosteroid Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Ophthalmic Corticosteroid Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Ophthalmic Corticosteroid Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Ophthalmic Corticosteroid Sales Value Share by Type (2021-2026) Table 23. Global Ophthalmic Corticosteroid Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospital Pharmacies Table 25. Significant Companies of Research Institute Table 26. Significant Companies of Online Pharmacies Table 27. Significant Companies of Retail Pharmacies Table 28. Significant Companies of Others Table 29. Global Ophthalmic Corticosteroid Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Ophthalmic Corticosteroid Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Ophthalmic Corticosteroid Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Ophthalmic Corticosteroid Sales Value Share by Application (2021-2026) Table 33. Global Ophthalmic Corticosteroid Sales Value Share by Application (2027-2032) Table 34. Global Ophthalmic Corticosteroid Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Ophthalmic Corticosteroid Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Ophthalmic Corticosteroid Sales Value Share by Region (2021-2026) Table 37. Global Ophthalmic Corticosteroid Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Ophthalmic Corticosteroid Sales Value Share by Region (2027-2032) Table 39. Global Ophthalmic Corticosteroid Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Ophthalmic Corticosteroid Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Ophthalmic Corticosteroid Sales Value Market Share by Country (2021-2026) Table 42. Global Ophthalmic Corticosteroid Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Ophthalmic Corticosteroid Sales Value Market Share by Country (2027-2032) Table 44. Novartis AG Company Information Table 45. Novartis AG Business Overview Table 46. Novartis AG Ophthalmic Corticosteroid Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Novartis AG Ophthalmic Corticosteroid Product Portfolio Table 48. Novartis AG Recent Development Table 49. Pfizer Company Information Table 50. Pfizer Business Overview Table 51. Pfizer Ophthalmic Corticosteroid Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Pfizer Ophthalmic Corticosteroid Product Portfolio Table 53. Pfizer Recent Development Table 54. GlaxoSmithKline Company Information Table 55. GlaxoSmithKline Business Overview Table 56. GlaxoSmithKline Ophthalmic Corticosteroid Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. GlaxoSmithKline Ophthalmic Corticosteroid Product Portfolio Table 58. GlaxoSmithKline Recent Development Table 59. Bayer AG Company Information Table 60. Bayer AG Business Overview Table 61. Bayer AG Ophthalmic Corticosteroid Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Bayer AG Ophthalmic Corticosteroid Product Portfolio Table 63. Bayer AG Recent Development Table 64. Sun Pharmaceutical Company Information Table 65. Sun Pharmaceutical Business Overview Table 66. Sun Pharmaceutical Ophthalmic Corticosteroid Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Sun Pharmaceutical Ophthalmic Corticosteroid Product Portfolio Table 68. Sun Pharmaceutical Recent Development Table 69. Regeneron Pharmaceuticals Company Information Table 70. Regeneron Pharmaceuticals Business Overview Table 71. Regeneron Pharmaceuticals Ophthalmic Corticosteroid Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Regeneron Pharmaceuticals Ophthalmic Corticosteroid Product Portfolio Table 73. Regeneron Pharmaceuticals Recent Development Table 74. Orchidia Company Information Table 75. Orchidia Business Overview Table 76. Orchidia Ophthalmic Corticosteroid Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Orchidia Ophthalmic Corticosteroid Product Portfolio Table 78. Orchidia Recent Development Table 79. Innovative Pharmaceuticals Company Information Table 80. Innovative Pharmaceuticals Business Overview Table 81. Innovative Pharmaceuticals Ophthalmic Corticosteroid Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Innovative Pharmaceuticals Ophthalmic Corticosteroid Product Portfolio Table 83. Innovative Pharmaceuticals Recent Development Table 84. General Pharmaceuticals Company Information Table 85. General Pharmaceuticals Business Overview Table 86. General Pharmaceuticals Ophthalmic Corticosteroid Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. General Pharmaceuticals Ophthalmic Corticosteroid Product Portfolio Table 88. General Pharmaceuticals Recent Development Table 89. Genentech Company Information Table 90. Genentech Business Overview Table 91. Genentech Ophthalmic Corticosteroid Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Genentech Ophthalmic Corticosteroid Product Portfolio Table 93. Genentech Recent Development Table 94. Bausch Health Company Information Table 95. Bausch Health Business Overview Table 96. Bausch Health Ophthalmic Corticosteroid Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Bausch Health Ophthalmic Corticosteroid Product Portfolio Table 98. Bausch Health Recent Development Table 99. Bausch and Lomb Company Information Table 100. Bausch and Lomb Business Overview Table 101. Bausch and Lomb Ophthalmic Corticosteroid Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Bausch and Lomb Ophthalmic Corticosteroid Product Portfolio Table 103. Bausch and Lomb Recent Development Table 104. Allergan Company Information Table 105. Allergan Business Overview Table 106. Allergan Ophthalmic Corticosteroid Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Allergan Ophthalmic Corticosteroid Product Portfolio Table 108. Allergan Recent Development Table 109. Alimera Sciences Company Information Table 110. Alimera Sciences Business Overview Table 111. Alimera Sciences Ophthalmic Corticosteroid Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Alimera Sciences Ophthalmic Corticosteroid Product Portfolio Table 113. Alimera Sciences Recent Development Table 114. Ajanta Pharma Company Information Table 115. Ajanta Pharma Business Overview Table 116. Ajanta Pharma Ophthalmic Corticosteroid Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Ajanta Pharma Ophthalmic Corticosteroid Product Portfolio Table 118. Ajanta Pharma Recent Development Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Ophthalmic Corticosteroid Product Image Figure 2. Global Ophthalmic Corticosteroid Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ophthalmic Corticosteroid Market Size (2021-2032) & (US$ Million) Figure 4. Global Ophthalmic Corticosteroid Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Dexamethasone Image Figure 8. Difluprednate Image Figure 9. Fluorometholone Image Figure 10. Loteprednol Image Figure 11. Others Image Figure 12. Global Ophthalmic Corticosteroid Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Ophthalmic Corticosteroid Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Ophthalmic Corticosteroid Sales Value Share by Type (2021-2032) Figure 15. Hospital Pharmacies Image Figure 16. Research Institute Image Figure 17. Online Pharmacies Image Figure 18. Retail Pharmacies Image Figure 19. Others Image Figure 20. Global Ophthalmic Corticosteroid Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Ophthalmic Corticosteroid Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Ophthalmic Corticosteroid Sales Value Share by Application (2021-2032) Figure 23. Global Ophthalmic Corticosteroid Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Ophthalmic Corticosteroid Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Ophthalmic Corticosteroid Sales Value (2021-2032) & (US$ Million) Figure 26. North America Ophthalmic Corticosteroid Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Ophthalmic Corticosteroid Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Ophthalmic Corticosteroid Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Ophthalmic Corticosteroid Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Ophthalmic Corticosteroid Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Ophthalmic Corticosteroid Sales Value (2021-2032) & (US$ Million) Figure 32. South America Ophthalmic Corticosteroid Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Ophthalmic Corticosteroid Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Ophthalmic Corticosteroid Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • Dexamethasone
  • Difluprednate
  • Fluorometholone
  • Loteprednol
  • Others
Applications
  • Hospital Pharmacies
  • Research Institute
  • Online Pharmacies
  • Retail Pharmacies
  • Others
Companies covered
  • Novartis AG
  • Pfizer
  • GlaxoSmithKline
  • Bayer AG
  • Sun Pharmaceutical
  • Regeneron Pharmaceuticals
  • Orchidia
  • Innovative Pharmaceuticals
  • General Pharmaceuticals
  • Genentech
  • Bausch Health
  • Bausch and Lomb
  • Allergan
  • Alimera Sciences
  • Ajanta Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Ophthalmic Corticosteroid Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Ophthalmic Corticosteroid Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Ophthalmic Corticosteroid Market Dynamics
  1. 2.1 Ophthalmic Corticosteroid Industry Trends
  2. 2.2 Ophthalmic Corticosteroid Industry Drivers
  3. 2.3 Ophthalmic Corticosteroid Industry Opportunities and Challenges
  4. 2.4 Ophthalmic Corticosteroid Industry Restraints
3 Ophthalmic Corticosteroid Market by Company
  1. 3.1 Global Ophthalmic Corticosteroid Company Revenue Ranking in 2025
  2. 3.2 Global Ophthalmic Corticosteroid Revenue by Company (2021-2026)
  3. 3.3 Global Ophthalmic Corticosteroid Company Ranking (2024-2026)
  4. 3.4 Global Ophthalmic Corticosteroid Company Manufacturing Base and Headquarters
  5. 3.5 Global Ophthalmic Corticosteroid Company Product Type and Application
  6. 3.6 Global Ophthalmic Corticosteroid Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Ophthalmic Corticosteroid Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Ophthalmic Corticosteroid Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Ophthalmic Corticosteroid Market by Type
  1. 4.1 Ophthalmic Corticosteroid Type Introduction
  2. 4.1.1 Dexamethasone
  3. 4.1.2 Difluprednate
  4. 4.1.3 Fluorometholone
  5. 4.1.4 Loteprednol
  6. 4.1.5 Others
  7. 4.2 Global Ophthalmic Corticosteroid Sales Value by Type
  8. 4.2.1 Global Ophthalmic Corticosteroid Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Ophthalmic Corticosteroid Sales Value by Type (2021-2032)
  10. 4.2.3 Global Ophthalmic Corticosteroid Sales Value Share by Type (2021-2032)
5 Ophthalmic Corticosteroid Market by Application
  1. 5.1 Ophthalmic Corticosteroid Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Research Institute
  4. 5.1.3 Online Pharmacies
  5. 5.1.4 Retail Pharmacies
  6. 5.1.5 Others
  7. 5.2 Global Ophthalmic Corticosteroid Sales Value by Application
  8. 5.2.1 Global Ophthalmic Corticosteroid Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Ophthalmic Corticosteroid Sales Value by Application (2021-2032)
  10. 5.2.3 Global Ophthalmic Corticosteroid Sales Value Share by Application (2021-2032)
6 Ophthalmic Corticosteroid Regional Value Analysis
  1. 6.1 Global Ophthalmic Corticosteroid Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Ophthalmic Corticosteroid Sales Value by Region (2021-2032)
  3. 6.2.1 Global Ophthalmic Corticosteroid Sales Value by Region: 2021-2026
  4. 6.2.2 Global Ophthalmic Corticosteroid Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Ophthalmic Corticosteroid Sales Value (2021-2032)
  7. 6.3.2 North America Ophthalmic Corticosteroid Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Ophthalmic Corticosteroid Sales Value (2021-2032)
  10. 6.4.2 Europe Ophthalmic Corticosteroid Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Ophthalmic Corticosteroid Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Ophthalmic Corticosteroid Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Ophthalmic Corticosteroid Sales Value (2021-2032)
  16. 6.6.2 South America Ophthalmic Corticosteroid Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Ophthalmic Corticosteroid Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Ophthalmic Corticosteroid Sales Value Share by Country, 2025 VS 2032
7 Ophthalmic Corticosteroid Country-level Value Analysis
  1. 7.1 Global Ophthalmic Corticosteroid Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Ophthalmic Corticosteroid Sales Value by Country (2021-2032)
  3. 7.2.1 Global Ophthalmic Corticosteroid Sales Value by Country (2021-2026)
  4. 7.2.2 Global Ophthalmic Corticosteroid Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Ophthalmic Corticosteroid Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Ophthalmic Corticosteroid Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Ophthalmic Corticosteroid Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Ophthalmic Corticosteroid Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Ophthalmic Corticosteroid Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 GlaxoSmithKline
  14. 8.3.1 GlaxoSmithKline Company Information
  15. 8.3.2 GlaxoSmithKline Business Overview
  16. 8.3.3 GlaxoSmithKline Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline Ophthalmic Corticosteroid Product Portfolio
  18. 8.3.5 GlaxoSmithKline Recent Developments
  19. 8.4 Bayer AG
  20. 8.4.1 Bayer AG Company Information
  21. 8.4.2 Bayer AG Business Overview
  22. 8.4.3 Bayer AG Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bayer AG Ophthalmic Corticosteroid Product Portfolio
  24. 8.4.5 Bayer AG Recent Developments
  25. 8.5 Sun Pharmaceutical
  26. 8.5.1 Sun Pharmaceutical Company Information
  27. 8.5.2 Sun Pharmaceutical Business Overview
  28. 8.5.3 Sun Pharmaceutical Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sun Pharmaceutical Ophthalmic Corticosteroid Product Portfolio
  30. 8.5.5 Sun Pharmaceutical Recent Developments
  31. 8.6 Regeneron Pharmaceuticals
  32. 8.6.1 Regeneron Pharmaceuticals Company Information
  33. 8.6.2 Regeneron Pharmaceuticals Business Overview
  34. 8.6.3 Regeneron Pharmaceuticals Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Regeneron Pharmaceuticals Ophthalmic Corticosteroid Product Portfolio
  36. 8.6.5 Regeneron Pharmaceuticals Recent Developments
  37. 8.7 Orchidia
  38. 8.7.1 Orchidia Company Information
  39. 8.7.2 Orchidia Business Overview
  40. 8.7.3 Orchidia Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Orchidia Ophthalmic Corticosteroid Product Portfolio
  42. 8.7.5 Orchidia Recent Developments
  43. 8.8 Innovative Pharmaceuticals
  44. 8.8.1 Innovative Pharmaceuticals Company Information
  45. 8.8.2 Innovative Pharmaceuticals Business Overview
  46. 8.8.3 Innovative Pharmaceuticals Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Innovative Pharmaceuticals Ophthalmic Corticosteroid Product Portfolio
  48. 8.8.5 Innovative Pharmaceuticals Recent Developments
  49. 8.9 General Pharmaceuticals
  50. 8.9.1 General Pharmaceuticals Company Information
  51. 8.9.2 General Pharmaceuticals Business Overview
  52. 8.9.3 General Pharmaceuticals Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  53. 8.9.4 General Pharmaceuticals Ophthalmic Corticosteroid Product Portfolio
  54. 8.9.5 General Pharmaceuticals Recent Developments
  55. 8.10 Genentech
  56. 8.10.1 Genentech Company Information
  57. 8.10.2 Genentech Business Overview
  58. 8.10.3 Genentech Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Genentech Ophthalmic Corticosteroid Product Portfolio
  60. 8.10.5 Genentech Recent Developments
  61. 8.11 Bausch Health
  62. 8.11.1 Bausch Health Company Information
  63. 8.11.2 Bausch Health Business Overview
  64. 8.11.3 Bausch Health Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bausch Health Ophthalmic Corticosteroid Product Portfolio
  66. 8.11.5 Bausch Health Recent Developments
  67. 8.12 Bausch and Lomb
  68. 8.12.1 Bausch and Lomb Company Information
  69. 8.12.2 Bausch and Lomb Business Overview
  70. 8.12.3 Bausch and Lomb Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bausch and Lomb Ophthalmic Corticosteroid Product Portfolio
  72. 8.12.5 Bausch and Lomb Recent Developments
  73. 8.13 Allergan
  74. 8.13.1 Allergan Company Information
  75. 8.13.2 Allergan Business Overview
  76. 8.13.3 Allergan Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Allergan Ophthalmic Corticosteroid Product Portfolio
  78. 8.13.5 Allergan Recent Developments
  79. 8.14 Alimera Sciences
  80. 8.14.1 Alimera Sciences Company Information
  81. 8.14.2 Alimera Sciences Business Overview
  82. 8.14.3 Alimera Sciences Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Alimera Sciences Ophthalmic Corticosteroid Product Portfolio
  84. 8.14.5 Alimera Sciences Recent Developments
  85. 8.15 Ajanta Pharma
  86. 8.15.1 Ajanta Pharma Company Information
  87. 8.15.2 Ajanta Pharma Business Overview
  88. 8.15.3 Ajanta Pharma Ophthalmic Corticosteroid Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Ajanta Pharma Ophthalmic Corticosteroid Product Portfolio
  90. 8.15.5 Ajanta Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst